Avecho Biotechnology (ASX:AVE) has signed a ten-year exclusive licensing agreement with Switzerland-based Sandoz Group AG for the commercialization of its cannabidiol (CBD) capsule aimed at treating insomnia in Australia, according to a Monday filing with the Australian bourse.
Under the deal, Avecho will receive an upfront payment of $3 million, milestone payments of up to $16 million, and royalties ranging from 14% to 19% on net sales, the filing said.
Avecho will continue funding the ongoing Phase III clinical trial and collaborate with Sandoz on regulatory approval from the Therapeutic Goods Administration, the filing added.
Once approved, Sandoz will market and distribute the product in Australia and Avecho will retain commercialization rights in all other territories, with Sandoz holding a right of first refusal, the company said.
Shares of the company fell 14% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。